From Johns Hopkins Psychedelic Newsletter Fall 2021:
Last year, Dr. Frederick Barrett published a study that showed psilocybin reduced neural activity in the claustrum during the period of drug action.
The claustrum, once thought to be the seat of consciousness, is a thin sheet of gray matter in the brain that reaches out to every other region in the brain.
The results showed that both the default mode network and areas of the brain believed to be responsible for setting attention and switching tasks may be disrupted during the effects of psilocybin, and alterations in the claustrum may account for these changes.
Read moreSome advocates claim that widespread psychedelic use will change the world for the better. But it’s not so simple.
Read moreThe largest psilocybin trial to date finds the psychedelic is effective in treating serious depression.
Eagerly awaited results of the largest-ever study of psilocybin were announced Tuesday, with Compass Pathways revealing the psychedelic drug was highly efficacious as a therapy for treatment-resistant depression.
Read moreCOMPASS Pathways, a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed the topline data shared today from an open-label study of psilocybin therapy for depression in cancer patients.
Within one week of a single administration of COMP360 psilocybin therapy, 50% of participants achieved remission in depression symptoms, which was sustained for the eight week follow-up period.
Read morehttps://www.youtube.com/watch?v=3LWNY70Oj4A
Carl Hart is a psychologist at Columbia University. Here he talks about heroin, cocaine, MDMA, alcohol & the role of drugs in society.
Read moreKeep reading for an interview with pioneering psychedelic activist Rick Doblin about the promise of MDMA therapy for PTSD, working with Republicans, and his hope for a drug-assisted global spiritual awakening.
Read moreRethinking the role of the default mode network in psychedelics: dissolving ego dissolution.
Read more